Androgen deprivation therapy in locally advanced prostate cancer

被引：1

作者：

Rossi, D. ^{[3
]}

Beuzeboc, P. ^{[4
]}

Staerman, F. ^{[5
]}

Timsit, M. -O ^{[6
]}

El Fegoun, A. Benchikh ^{[1
,2
]}

机构：

[1] CHRU, Hop Huriez, Serv Urol, F-59037 Lille, France

[2] Hop Bichat Claude Bernard, Serv Urol, F-75018 Paris, France

[3] Hop Nord Marseille, Serv Urol, F-13915 Marseille 20, France

[4] Inst Curie, Med Oncol Serv, F-75248 Paris 05, France

[5] Hop Robert Debre, Serv Urol Androl, F-51092 Reims, France

[6] Hop Necker Enfants Malad, Serv Urol, F-75743 Paris 15, France

来源：

PROGRES EN UROLOGIE | 2010年 / 20卷

关键词：

Locally advanced prostate cancer; Androgen deprivation therapy; Castrate resistant prostate cancer; FLUTAMIDE; ADJUVANT; BICALUTAMIDE; RADIOTHERAPY; SUPPRESSION; CARCINOMA; ANTIGEN; METAANALYSIS; COMBINATION; MONOTHERAPY;

D O I：

10.1016/S1166-7087(10)70031-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

In case of biochemical recurrence after radical prostatectomy, hormonal treatments are equally efficient. Early hormonal treatment after biochemical recurrence reduces specific mortality, local and metastatic progression. In locally advanced prostate cancer, adjuvant radiation therapy after biochemical recurrence reduces local and metastatic recurrence. Withdrawal of the steroid hormone should be the first maneuver after primary hormonal therapy failure. Second generation anti-androgens (abiraterone and MDV 3100) should be released soon. These new hormonal agents are in clinical trials and show promising activity in patients with CRPC. (C) 2010 Published by Elsevier Masson SAS

引用

页码：S68 / S71

页数：4

共 50 条

[31] Androgen deprivation therapy for prostate cancer
Singer, Eric A.
Golijanin, Dragan J.
Miyamoto, Hiroshi
Messing, Edward M.
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (02) : 211 - 228
[32] Androgen deprivation therapy for advanced prostate cancer in Sarawak General Hospital
Chan, S. H.
Rufaey, A.
Lim, M. S.
Toh, C. C.
Teh, G. C.
Lei, C. M.
BJU INTERNATIONAL, 2015, 116 : 25 - 26
[33] Androgen Deprivation Therapy for Advanced Prostate Cancer: Can Evolution Be Accelerated?
Mohler, James L.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (06): : 701 - 703
[34] Cognitive Effects of Androgen Deprivation Therapy in Men With Advanced Prostate Cancer
Calleary, John G.
UROLOGY, 2017, 103 : 171 - 172
[35] Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Shore, Neal D.
Saad, Fred
Cookson, Michael S.
George, Daniel J.
Saltzstein, Daniel R.
Tutrone, Ronald
Akaza, Hideyuki
Bossi, Alberto
van Veenhuyzen, David F.
Selby, Bryan
Fan, Xiaolin
Kang, Vicky
Walling, Jackie
Tombal, Bertrand
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23): : 2187 - 2196
[36] The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer
Reiss, Allison B.
Vasalani, Samantha
Albert, Jacqueline
Drewes, Wendy
Li, Kathleen
Srivastava, Ankita
De Leon, Joshua
Katz, Aaron E.
MEDICINA-LITHUANIA, 2024, 60 (11):
[37] Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer
Klotz, Laurence
CURRENT UROLOGY REPORTS, 2013, 14 (03) : 159 - 167
[38] Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer
Marlon Perera
Matthew J. Roberts
Laurence Klotz
Celestia S. Higano
Nathan Papa
Shomik Sengupta
Damien Bolton
Nathan Lawrentschuk
Nature Reviews Urology, 2020, 17 : 469 - 481
[39] Current Approach to Androgen Deprivation Therapy in Patients With Advanced Prostate Cancer
Heidenreich, Axel
EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (11) : 776 - 781
[40] Cognitive Effects of Androgen Deprivation Therapy in Men With Advanced Prostate Cancer
Gunlusoy, Bulent
Ceylan, Yasin
Koskderelioglu, Asli
Gedizlioglu, Muhtesem
Degirmenci, Tansu
Ortan, Pinar
Kozacioglu, Zafer
UROLOGY, 2017, 103 : 167 - 171

← 1 2 3 4 5 →